Provided by Tiger Trade Technology Pte. Ltd.

Ovid Therapeutics Inc.

2.30
-0.1600-6.50%
Post-market: 2.340.0400+1.74%17:25 EDT
Volume:2.02M
Turnover:4.75M
Market Cap:347.30M
PE:-9.89
High:2.45
Open:2.42
Low:2.29
Close:2.46
52wk High:2.72
52wk Low:0.2425
Shares:151.00M
Float Shares:120.00M
Volume Ratio:0.49
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2325
EPS(LYR):-0.2325
ROE:-17.51%
ROA:-21.82%
PB:2.66
PE(LYR):-9.89

Loading ...

Ra Capital Management, L.p. Reports 9.9% Passive Stake in Ovid Therapeutics as of Dec 11 - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

BRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350

Reuters
·
Dec 18, 2025

Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Neural Hyperexcitability

Reuters
·
Dec 18, 2025

Ovid Therapeutics Inc - Ov350 Shows Good Safety Profile Supporting Kcc2 Portfolio Advancement

THOMSON REUTERS
·
Dec 18, 2025

Ovid Therapeutics Inc - Announces Phase 1 Results for Ov350

THOMSON REUTERS
·
Dec 18, 2025

Ovid Therapeutics Inc - No Treatment-Related Safety Findings or Serious Adverse Events

THOMSON REUTERS
·
Dec 18, 2025

Ovid Therapeutics Announces Phase 1/1b Clinical Trial Submission for Oral KCC2 Activator OV4071

Reuters
·
Dec 18, 2025

Ovid Therapeutics Inc. Held Special Shareholder Meeting

Reuters
·
Dec 12, 2025

Ovid Therapeutics Names Dr. Petra Kaufmann as Chief Medical Officer

Reuters
·
Dec 02, 2025

Ovid Therapeutics Appoints DR. Petra Kaufmann as Chief Medical Officer

THOMSON REUTERS
·
Dec 02, 2025

Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Drug-Resistant Seizures and Neural Hyperexcitability

Reuters
·
Nov 14, 2025

BTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)

TIPRANKS
·
Nov 14, 2025

Ovid Therapeutics Q3 revenue slightly beats expectations

Reuters
·
Nov 12, 2025

Ovid Therapeutics reports Q3 revenue of $132,000 and R&D expenses of $5.9 million

Reuters
·
Nov 12, 2025

BRIEF-Ovid Therapeutics Q3 EPS USD -0.17

Reuters
·
Nov 12, 2025

Ovid Therapeutics Names Meg Alexander as CEO

Reuters
·
Nov 12, 2025

Ovid Therapeutics Q3 Revenue USD 132 Thousand VS. Ibes Estimate USD 153.3 Thousand

THOMSON REUTERS
·
Nov 12, 2025

Ovid Therapeutics Inc - Jeremy M. Levin to Transition to Executive Chair of Bod

THOMSON REUTERS
·
Nov 12, 2025

Ovid Therapeutics Inc - Meg Alexander Appointed CEO Effective January 1, 2026

THOMSON REUTERS
·
Nov 12, 2025

Press Release: Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Dow Jones
·
Nov 12, 2025